ES2042582T3 - Un procedimiento para preparar una composicion de sustancia que tiene una actividad fisiologica y nutricional util. - Google Patents

Un procedimiento para preparar una composicion de sustancia que tiene una actividad fisiologica y nutricional util.

Info

Publication number
ES2042582T3
ES2042582T3 ES87310416T ES87310416T ES2042582T3 ES 2042582 T3 ES2042582 T3 ES 2042582T3 ES 87310416 T ES87310416 T ES 87310416T ES 87310416 T ES87310416 T ES 87310416T ES 2042582 T3 ES2042582 T3 ES 2042582T3
Authority
ES
Spain
Prior art keywords
preparing
procedure
substance composition
useful physiological
nutritional activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87310416T
Other languages
English (en)
Inventor
Shlomo Yehuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bar Ilan University
Original Assignee
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL80786A external-priority patent/IL80786A/xx
Priority claimed from IL84273A external-priority patent/IL84273A0/xx
Application filed by Bar Ilan University filed Critical Bar Ilan University
Application granted granted Critical
Publication of ES2042582T3 publication Critical patent/ES2042582T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION UTIL EN UN METODO PARA TRATAR A UN MAMIFERO CON OBJETO DE INDUCIR MEJORA DE LA MEMORIA, ANALGESIA, REGULACION DEL SUEÑO Y/O INHIBICION DE LOS SINTOMAS DE SENILIDAD, QUE CONTIENE ENTRE 13,0 Y 27,5% EN PESO DE ACIDO LINOLENICO Y EL RESTO ACIDO LINOLEICO. TAMBIEN SE PUEDEN USAR DERIVADOS FISIOLOGICAMENTE HIDROLIZABLES Y DERIVADOS ACEPTABLES DESDE EL PUNTO DE VISTA FARMACOLOGICA DE ESTOS ACIDOS. LA COMBINACION DE ACIDOS ESPECIFICADA SE PUEDE ADMINISTRAR COMO FORMULACION FARMACEUTICA O COMO COMPOSICION NUTRIENTE.
ES87310416T 1986-11-26 1987-11-25 Un procedimiento para preparar una composicion de sustancia que tiene una actividad fisiologica y nutricional util. Expired - Lifetime ES2042582T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL80786A IL80786A (en) 1986-11-26 1986-11-26 Physiologically active and nutritional composition containing a mixture of linolenic and linoleic acids
IL84273A IL84273A0 (en) 1987-10-25 1987-10-25 Physiologically active and nutritional composition

Publications (1)

Publication Number Publication Date
ES2042582T3 true ES2042582T3 (es) 1993-12-16

Family

ID=26321617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87310416T Expired - Lifetime ES2042582T3 (es) 1986-11-26 1987-11-25 Un procedimiento para preparar una composicion de sustancia que tiene una actividad fisiologica y nutricional util.

Country Status (9)

Country Link
US (1) US4851431A (es)
EP (1) EP0275643B1 (es)
JP (1) JP2675560B2 (es)
CY (1) CY1610A (es)
DE (1) DE3769458D1 (es)
ES (1) ES2042582T3 (es)
GR (1) GR3001805T3 (es)
HK (1) HK28092A (es)
SG (1) SG75691G (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599840A (en) * 1986-11-26 1997-02-04 Bar Ilan University Physiologically active and nutritional composition
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
IL91802A (en) * 1988-10-27 1994-05-30 Univ Bar Ilan Preparations containing linoleic acid history for the treatment of Alzheimer's, similar brain diseases, and epilepsy
DE3924607A1 (de) * 1989-07-21 1991-01-24 Singer Peter Dr Sc Med Diaetetisches nahrungs- oder genussmittel
JPH08768B2 (ja) * 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
GB2254556B (en) * 1991-04-11 1995-04-12 Fisons Plc Formulations containing linolenic acid
US5405613A (en) * 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
US5780451A (en) * 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
US5952314A (en) 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
US5612380A (en) * 1994-09-27 1997-03-18 The Scripps Research Institute Method for sleep induction
AU701945B2 (en) * 1994-09-27 1999-02-11 Scripps Research Institute, The Method for sleep induction
GB9423625D0 (en) * 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
DE69833791D1 (de) * 1997-11-24 2006-05-04 Scripps Research Inst Hemmer der "gap junction communication"
IL125731A (en) 1998-08-11 2004-06-20 Zvi Yehuda Acylates which are products of neurotransmitters and essential fatty acids, pharmaceutical compositions containing them, use of such acylates in the manufacture of medicaments, and method for treating nervous diseases in non-human animals
US20050037065A1 (en) * 1999-05-27 2005-02-17 Drugtech Corporation Nutritional formulations
WO2000077179A2 (en) * 1999-06-16 2000-12-21 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
MXPA06000580A (es) * 2003-07-21 2006-03-30 Unilever Nv Auxiliar de la funcion cognitiva.
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
FR2885528A1 (fr) * 2005-05-13 2006-11-17 Persee Medica Composition utile pour traiter ou prevenir les troubles lies a un dereglement de l'horloge biologique
FR2912918A1 (fr) * 2007-02-27 2008-08-29 Persee Medica Soc Par Actions Utilisation d'acides gras polyinsatures et de flavonoides en tant qu'agents actifs dans une composition pour la prevention et/ou le traitement des cephalees.
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
CN108771053A (zh) * 2018-05-24 2018-11-09 广东生命号药业股份有限公司 一种改善记忆力的饮料及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31836A (en) * 1861-03-26 Robert taylor
US3011949A (en) * 1958-06-10 1961-12-05 Anthony G Bilotti Method of promoting release of active ingredients from slab chewing gum and product
US3962416A (en) * 1971-01-25 1976-06-08 Sol Katzen Preserved nutrients and products
BE791350A (nl) * 1971-11-15 1973-05-14 Stichting Bedrijven Van Het Werkwijze voor de bereiding van een melkeiwit-coprecipitaat
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
US4097604A (en) * 1975-12-18 1978-06-27 Oxford Hill, Ltd. Method of treating and controlling gingivitis
FR2380775A1 (fr) * 1977-02-22 1978-09-15 Sederma Sarl Composition " apres-epilation " favorisant un ralentissement progressif de la repousse des poils
IE47777B1 (en) * 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
USRE31836E (en) 1979-05-18 1985-02-19 Efamol Limited Pharmaceutical and dietary composition
IE53332B1 (en) * 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
EP0071357B1 (en) * 1981-07-14 1985-01-02 Efamol Limited Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4668704A (en) * 1982-08-09 1987-05-26 Regents Of The University Of California Method for protecting and healing gastro-duodenal mucosa and the liver of mammals
US4670468A (en) * 1982-08-09 1987-06-02 Regents Of The University Of California Method for protecting and healing gastroduodenal mucosa and the liver of mammals
GB2134782B (en) * 1982-09-22 1987-03-04 Sentrachem Ltd Anti-cancer compositions containing higher fatty acids
GB8425006D0 (en) * 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids

Also Published As

Publication number Publication date
JPS63188364A (ja) 1988-08-03
HK28092A (en) 1992-04-24
SG75691G (en) 1991-11-15
DE3769458D1 (de) 1991-05-23
CY1610A (en) 1992-07-10
EP0275643B1 (en) 1991-04-17
JP2675560B2 (ja) 1997-11-12
US4851431A (en) 1989-07-25
EP0275643A1 (en) 1988-07-27
GR3001805T3 (en) 1992-11-23

Similar Documents

Publication Publication Date Title
ES2042582T3 (es) Un procedimiento para preparar una composicion de sustancia que tiene una actividad fisiologica y nutricional util.
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES509647A0 (es) Procedimiento para preparar una polilactida.
ES2102367T3 (es) Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2143132T3 (es) Monohidratos de derivado de acido aminobenceno-sulfonico y su metodo de preparacion.
ES2059497T3 (es) Derivados del acido tiazolidin-4-carboxilico dotados de actividad farmacologica.
ES2032394T3 (es) Procedimiento para preparar derivados de tienoimidazol sustituidos.
PT92821A (pt) Processo para a preparacao composicoes farmaceuticas para o combate de doencas do tipo psoriase, bem como doencas inflamatorias, incorporando azelastina como substancia activa
PT82987B (pt) Processo para a preparacao de novos de derivados de acidos carboxilicos bem como de composicoes farmaceuticas que os contem
ES2060173T3 (es) Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
ES2052761T3 (es) Nuevos esteres del acido androstano 17-carboxilico, procedimiento para su preparacion y medicamento que los contiene.
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
ES2091183T3 (es) Metodo para mejorar el sueño.
NO306762B1 (no) Anvendelse av lanolinderivater sammen med polyetylenglykoletere, blanding derav og transdermalt terapeutisk system
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES544664A0 (es) Procedimiento para el diagnostico in vitro del sexo
ES2036533T3 (es) Derivados de 1,6-naftiridina, procedimientos para su obtencion y de medicamentos que los contienen para el tratamiento de enfermedades de los vasos sanguineos.
ES2062997T3 (es) Vinilcefalosporinas sustituidas, procedimiento para su fabricacion y su uso como medicamento.
AR008695A1 (es) Composiciones farmaceuticas estabilizadas, basadas en la asociacion de quinupristina / dalfopristina; procedimiento para prepararlas, utilizacion dedichas composiciones y utilizacion del acido metansulfonico o del acido clorhidrico en la estabilizacion de dichas composiciones.
ES8502435A1 (es) Un metodo para preparar 2(1h)-piridinonas
ES8601687A1 (es) Procedimiento para producir una tableta de administracion oral de liberacion controlada, independiente del ph

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 275643

Country of ref document: ES